A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures.

https://escholarship.org/uc/item/6m95q0r6

The Journal of bone and joint surgery. American volume, 102(8)

0021-9355

Schemitsch, Emil H
Miclau, Theodore
Karachalios, Theofilos
et al.

2020-04-01

10.2106/jbjs.19.00790

Peer reviewed
A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures

Emil H. Schemitsch, MD, FRCS(C), Theodore Miclau, MD, Theofilos Karachalios, MD, Lauren L. Nowak, MSc, Parag Sancheti, FRCS(Ed), MS(Orth), MCh(UK), PhD, Rudolf W. Poolman, MD, PhD, John Caminis, MD, Nadia Daizadeh, PhD, Ricardo E. Dent-Acosta, MD, Ogo Egbuna, MD, MSc, Arkadi Chines, MD, Judy Maddox, DO, Andreas Grauer, MD, and Mohit Bhandari, MD, PhD

Background: Romosozumab is a bone-forming antibody that increases bone formation and decreases bone resorption. We conducted a double-blinded, randomized, phase-2, dose-finding trial to evaluate the effect of romosozumab on the clinical outcomes of open reduction and internal fixation of intertrochanteric or femoral neck hip fractures.

Methods: Patients (55 to 94 years old) were randomized 2:3:3:3 to receive 3 subcutaneous injections of romosozumab (70, 140, or 210 mg) or a placebo postoperatively on day 1 and weeks 2, 6, and 12. The primary end point was the difference in the mean timed “Up & Go” (TUG) score over weeks 6 to 20 for romosozumab versus placebo. Additional end points included the time to radiographic evidence of healing and the score on the Radiographic Union Scale for Hip (RUSH).

Results: A total of 332 patients were randomized: 243 to receive romosozumab (70 mg, n = 60; 140 mg, n = 93; and 210 mg, n = 90) and 89 to receive a placebo. Although TUG scores improved during the study, they did not differ significantly between the romosozumab and placebo groups over weeks 6 to 20 (p = 0.198). The median time to radiographic evidence of healing was 16.4 to 16.9 weeks across treatment groups. The RUSH scores improved over time across treatment groups but did not differ significantly between the romosozumab and placebo groups. The overall safety and tolerability profile of romosozumab was comparable with that of the placebo.

Conclusions: Romosozumab did not improve the fracture-healing-related clinical and radiographic outcomes in the study population.

Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

Hip fractures are a devastating clinical manifestation of osteoporosis. The almost 2 million hip fractures that occur each year in people older than 50 years are associated with substantial morbidity, excess mortality, and high health-care costs1-4. Almost all hip fractures are treated surgically. In the elderly, compromised mechanical and biological capacity, comorbidities, and possible complications make the management of hip fractures challenging, and the acceleration of fracture-healing is the desirable therapeutic outcome5. The systemic bone-forming agent teriparatide was investigated to assess its ability to accelerate fracture-healing, and while the results of a retrospective analysis were promising6, randomized controlled studies yielded inconclusive results7-9.

Romosozumab is a bone-forming antibody that increases bone formation and decreases bone resorption and is indicated to treat osteoporosis in postmenopausal women at high risk for fracture10. Romosozumab increased bone mineral density (BMD)11; reduced the prevalence of vertebral and clinical (a composite of nonvertebral and symptomatic vertebral) fractures (compared with a placebo)12; and, when followed by alendronate, reduced the risk of vertebral, nonvertebral, and hip fractures (compared with alendronate alone)13.

Disclosure: This study was funded by Amgen, Inc. and UCB Pharma. On the Disclosure of Potential Conflicts of Interest forms, which are provided with the online version of the article, one, or more of the authors checked “yes” to indicate that the author had a relevant financial relationship in the biomedical arena outside the submitted work (including employment with Amgen Inc., the sponsor of the study) (http://links.lww.com/JBJS/F702).

A data-sharing statement is provided with the online version of the article (http://links.lww.com/JBJS/F704).

Copyright © 2020 The Authors. Published by The Journal of Bone and Joint Surgery, Incorporated. All rights reserved. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Preclinical studies showed that romosozumab enhances fracture-healing. Romosozumab significantly increased bone mass and strength at the fracture site in a closed femoral fracture model in rats by week 7 and in a fibular osteotomy model in cynomolgus monkeys by week 10, promoted fracture-healing and increased bone strength in a mouse femoral osteotomy model by week 6, and increased the area of newly formed bone in a rat femoral osteotomy model by week 6.

On the basis of these preclinical data, we hypothesized that romosozumab would accelerate healing of hip fractures and improve physical functioning of human subjects. We conducted a phase-2, dose-finding trial to evaluate the effect of romosozumab administered over 12 weeks on the clinical outcomes of open reduction and internal fixation of intertrochanteric or femoral neck hip fractures.

**Materials and Methods**

**Study Design**

This phase-2, multicenter, international, randomized, double-blinded, placebo-controlled study enrolled patients with an acute, unilateral, low-energy hip fracture (sustained from a standing height or less) and treated with open reduction and internal fixation. The study was registered in ClinicalTrials.gov (NCT01081678). Dosing regimens were based on phase-1 single and multiple-dose studies that demonstrated a pharmacologic effect of romosozumab on bone formation markers. An interactive voice response system was used to randomize patients to receive 70, 140, or 210 mg of romosozumab or a placebo. The placebo group received 3 vials of placebo solution; the 70-mg group, 1 vial containing 70 mg of romosozumab and 2 vials of matched placebo solution; the 140-mg group, 2 vials each containing 70 mg of romosozumab and 1 vial of matched placebo solution; and the 210-group, 3 vials each containing 70 mg of romosozumab. Black arrows indicate study visits with administration of the investigational product, gray arrows indicate study visits without administration of the investigational product, and brown arrows indicate telephone visits. D = day, SC = subcutaneous, W = week.
substitutes at the time of fracture fixation, major polytrauma or substantial axial trauma, and a pathological fracture or history of metabolic or bone disease (except osteoporosis). All eligibility criteria are listed in the Appendix.

**Study Procedures**

Anteroposterior and lateral (or oblique) radiographs of the proximal part of the femur were obtained at every clinic visit starting from week 2. The quality of surgical fixation and radiographic evidence of fracture-healing were determined by independent reviewers (orthopaedic/trauma surgeons and radiologists), blinded to treatment. Radiographic evaluation ended once healing was confirmed, except for mandatory radiographs at weeks 52 (end of study) and 104 (long-term follow-up).

The TUG test is a validated and reliable tool used to assess functional mobility of persons with impaired mobility. Since TUG correlates well with activities of daily living, it was used to assess functional recovery in our study. Clinicians timed the patient while they stood up from a seated position in a chair, walked 3 m, turned around, walked back to the chair, and returned to the seated position. Study staff were trained on how to administer the TUG test via a training video.

The RUSH score is a validated and reliable tool developed to objectively assess hip (femoral neck) fracture-healing after surgical repair. RUSH quantifies 10 measures of fracture-healing: cortical bridging and disappearance of the cortical fracture line in the anterior, posterior, medial, and lateral femoral neck regions and trabecular consolidation and disappearance of the trabecular fracture line (trabecular healing is

![Flow of patients through the study](image)
| TABLE I Baseline Demographics and Disease Characteristics | Subcutaneous Romosozumab | Placebo (N = 89) | 70 mg (N = 60) | 140 mg (N = 93) | 210 mg (N = 90) | Total Romosozumab Group (N = 243) |
| --- | --- | --- | --- | --- | --- | --- |
| **Sex (no. [%])** | | | | | | |
| Female | | 67 (75.3) | 42 (70.0) | 64 (68.8) | 55 (61.1) | 161 (66.3) |
| Male | | 22 (24.7) | 18 (30.0) | 29 (31.2) | 35 (38.9) | 82 (33.7) |
| **Median age (range) (yr)** | | 78 (55-91) | 78.5 (55-94) | 79 (55-94) | 79 (55-93) | 79 (55-94) |
| **Geriatric age group (no. [%])** | | | | | | |
| ≥65 yr | | 79 (88.8) | 52 (86.7) | 76 (81.7) | 79 (87.8) | 207 (85.2) |
| ≥75 yr | | 54 (60.7) | 37 (61.7) | 56 (60.2) | 56 (62.2) | 149 (61.3) |
| **Race (no. [%])** | | | | | | |
| White | | 77 (86.5) | 52 (86.7) | 81 (87.1) | 70 (77.8) | 203 (83.5) |
| Asian | | 12 (13.5) | 7 (11.7) | 11 (11.8) | 19 (21.1) | 37 (15.2) |
| Black | | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.1) | 1 (0.4) |
| Hispanic | | 0 (0.0) | 1 (1.7) | 1 (1.1) | 0 (0.0) | 2 (0.8) |
| **Geographic region (no. [%])** | | | | | | |
| Eastern Europe | | 27 (30.3) | 22 (36.7) | 41 (44.1) | 25 (27.8) | 88 (36.2) |
| Western Europe | | 30 (33.7) | 15 (25.0) | 29 (31.2) | 27 (30.0) | 71 (29.2) |
| India | | 10 (11.2) | 7 (11.7) | 10 (10.8) | 18 (20.0) | 35 (14.4) |
| North America | | 14 (15.7) | 11 (18.3) | 4 (4.3) | 8 (8.9) | 23 (9.5) |
| Latin America | | 5 (5.6) | 4 (6.7) | 6 (6.5) | 9 (10.0) | 19 (7.8) |
| Australia and New Zealand | | 1 (1.1) | 1 (1.7) | 2 (2.2) | 2 (2.2) | 5 (2.1) |
| Other | | 2 (2.2) | 0 (0.0) | 1 (1.1) | 1 (1.1) | 2 (0.8) |
| **ASA classification* (no. [%])** | | | | | | |
| Class I | | 24 (27.0) | 19 (31.7) | 32 (34.4) | 32 (35.6) | 83 (34.2) |
| Class II | | 49 (55.1) | 30 (50.0) | 43 (46.2) | 43 (47.8) | 116 (47.7) |
| Class III | | 16 (18.0) | 9 (15.0) | 17 (18.3) | 14 (15.6) | 40 (16.5) |
| Class IV | | 0 (0.0) | 2 (3.3) | 1 (1.1) | 1 (1.1) | 4 (1.6) |
| **Mean body mass index (SD)*† (kg/m²)** | | | | | | |
| Women | | 25.0 (4.5) | 24.4 (3.5) | 23.6 (4.0) | 23.7 (3.4) | 23.9 (3.6) |
| Men | | 24.7 (4.7) | 24.4 (2.9) | 25.2 (4.6) | 24.1 (4.2) | 24.5 (4.1) |
| **Location of hip fracture (no. [%])** | | | | | | |
| Intertrochanteric | | 55 (61.8) | 41 (68.3) | 67 (72.0) | 62 (68.9) | 170 (70.0) |
| Intertrochanteric extending into subtrochanteric region | | 21 (23.6) | 11 (18.3) | 15 (16.1) | 19 (21.1) | 45 (18.5) |
| Femoral neck | | 13 (14.6) | 8 (13.3) | 11 (11.8) | 9 (10.0) | 28 (11.5) |
| **Mechanism of injury (no. [%])** | | | | | | |
| Fall from standing height or less | | 76 (85.4) | 54 (90.0) | 82 (88.2) | 79 (87.8) | 215 (88.5) |
| Fall on stairs, steps, or curb | | 8 (9.0) | 2 (3.3) | 9 (9.7) | 3 (3.3) | 14 (5.8) |
| Fall from −20 in (51 cm) | | 3 (3.4) | 2 (3.3) | 2 (2.2) | 2 (2.2) | 6 (2.5) |
| Fall from higher than −20 in (51 cm) | | 2 (2.2) | 2 (3.3) | 0 (0.0) | 4 (4.4) | 6 (2.5) |
| Spontaneous (stress) fracture | | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (2.2) | 2 (0.8) |
| **Method of internal fixation (no. [%])** | | | | | | |
| Intramedullary nail | | 49 (55.1) | 33 (55.0) | 52 (55.9) | 49 (54.4) | 134 (55.1) |
| Sliding hip screw | | 31 (34.8) | 22 (36.7) | 32 (34.4) | 35 (38.9) | 89 (36.6) |
| Cancellous screws | | 9 (10.1) | 5 (8.3) | 9 (9.7) | 6 (6.7) | 20 (8.2) |

*Class I = healthy patient with no medical problems, Class II = mild systemic disease, Class III = severe systemic disease but not incapacitating, and Class IV = severe systemic disease that is a constant threat to life. †SD = standard deviation.
indicated by consolidation of the matrix and disappearance of the fracture line). Each of the 10 healing measures are scored as 1, 2, or 3; a minimum total score of 10 indicates no healing, and a maximum total score of 30 indicates complete healing.

Adverse events were recorded at each study visit and coded using MedDRA (Medical Dictionary for Regulatory Activities), version 15.1. To determine the immunogenicity of romosozumab and its relationship to safety, blood samples taken on day 1 and weeks 6, 12, 20, 24, 36, and 52 were assessed for the presence of anti-romosozumab binding and neutralizing antibodies.

**Statistical Analyses**
The sample size calculation assumed that romosozumab would reduce the mean TUG scores over weeks 6 to 20 by 25% compared with the score associated with a placebo, which was approximately 36 seconds according to Ingemarsson et al.\(^2\)\(^7\). Allowing for a 20% withdrawal rate by week 24 and a type-I error of 0.05, 266 patients were required (133 per arm) to detect a 25% difference in TUG scores with 90% power assuming a standard deviation of 15 seconds.

### TABLE II Radiographic Evidence of Healing*

|                                | Placebo (N = 87) | 70 mg (N = 60) | 140 mg (N = 89) | 210 mg (N = 89) |
|--------------------------------|------------------|----------------|-----------------|-----------------|
| Patients with radiographic healing at wk 24 | CIF estimate (95% CI) (%) | 73.2 (62.6-82.8) | 78.6 (66.7-88.5) | 72.8 (62.3-82.3) | 66.2 (55.1-77.1) |
| Patients with radiographic healing at wk 52 | CIF estimate (95% CI) (%) | 93.2 (85.1-97.8) | 90.1 (79.5-96.6) | 93.1 (85.6-97.4) | 89.1 (79.9-95.3) |
| Median time to radiographic evidence of healing† | CIF estimate (95% CI) (wk) | 16.4 (15.3-20.1) | 16.9 (12.9-20.3) | 16.6 (13.3-20.9) | 16.9 (13.3-20.9) |
| HR‡ (95% CI), p value | 1.1 (0.7-1.6), p = 0.79 | 1.1 (0.8-1.6), p = 0.62 | 1.1 (0.7-1.6), p = 0.76 |

\*N = number of randomized patients who received ≥1 dose of investigational product. Data are presented as point estimates. CIF = cumulative incidence function, CI = confidence interval, and HR = hazard ratio. †From fracture fixation date. ‡HR is based on a Cox proportional-hazards model with treatment groups as the independent variable, stratified by randomization strata, and adjusted for sex, prefracture community dwelling status, use of prefracture walking aid, and quality of surgical fixation. An HR of >1 favors romosozumab.
error of 5%, the calculation showed that approximately 90 patients per group (and 60 for the 70-mg group) would provide ≥80% power to detect differences between romosozumab and placebo with the use of a 2-sided t test.

A linear mixed-effects model was fit with log-transformed TUG scores as the dependent variable and treatment group, sex, prefracture community dwelling status, prefracture use of a walking aid, geographic region, quality of surgical fixation, visit week, and visit-by-treatment interaction as independent variables, stratified by the randomization strata.

The difference in the least-squares-mean (LSM) TUG scores over weeks 6 to 20 between the romosozumab and placebo groups was determined. Measurements obtained after unplanned revision surgery (indicative of poor healing) were assigned the visit-dependent worst value, which was imputed if a patient could not perform or complete the TUG test. Results based on log-transformed data were back-transformed to seconds.

For time to radiographic evidence of healing, a proportional-hazards model was fit, adjusted for sex, prefracture community dwelling status, prefracture use of a walking aid, and quality of surgical fixation as independent covariates, stratified by the randomization strata. Patients were censored for unplanned revision surgery before radiographic evidence of healing. The estimate of the treatment effect was the hazard ratio (with 95% confidence interval [CI]) of romosozumab versus placebo with respect to time to revision-surgery-free healing. The cumulative incidence function was determined for each treatment group.

Treatment differences in the total RUSH score were assessed using the van Elteren stratified rank test (adjusting for randomization strata) at each time point. Missing scores were imputed using the last-observation-carried-forward approach.

The final analysis was conducted after completion of the week-52 assessments. Analyses of efficacy and safety were performed after unblinding and included all randomized patients who had received ≥1 dose of the investigational product.

Results

Patient Disposition and Baseline Characteristics

A total of 332 patients were randomized at 63 sites in 22 countries (see Appendix Table) between June 2010 and January 2013: 243 were randomized to receive romosozumab (70 mg, N = 60; 140 mg, N = 93; 210 mg, N = 90) and 89, to receive a placebo. Overall, 325 patients received ≥1 dose of the investigational product, and 263 (79.2%) and 229 (69.0%) completed 24 and 52 weeks of the study, respectively. Discontinuation rates and reasons for discontinuation were comparable among the treatment groups (Fig. 2).

Baseline demographics and disease characteristics were generally balanced across the treatment groups; however, there was a higher percentage of women in the placebo group (75.3%) than in the total romosozumab group (66.3%) and a higher percentage of Asian patients in the 210-mg romosozumab group (21.1%) than in the other groups (11.7% to 13.5%) (Table I). Across the treatment groups, approximately 80% of the patients were classified as either healthy or having mild, systematic disease according to the American Society of Anesthesiologists (ASA) classification; 61.8% to 72.0% of the patients had an intertrochanteric hip fracture, 16.1% to 23.6% had an intertrochanteric hip fracture with extension into the subtrochanteric region, and 10.0% to 14.6% had a femoral neck fracture. Most patients were injured falling from a standing height or less. Most internal fixation implants were intramedullary nails (range across groups, 54.4% to 55.9%).

Efficacy

TUG Scores by Visit

The LSM TUG scores improved from weeks 2 to 52 for each treatment group (Fig. 3). From weeks 2 to 20, the LSM TUG scores for the placebo and 70-mg, 140-mg, and 210-mg romosozumab groups improved from 82 to 24, 71 to 22, 77 to 23, and 86 to 29 seconds, respectively; the scores leveled off after week 20. There were no significant differences in the LSM TUG scores between the treatment groups.
scores over weeks 6 to 20 between the romosozumab and placebo groups (primary end point, p = 0.198). At week 52, the LSM (and 95% CI) TUG score ratios (romosozumab:placebo) were 0.9 (0.7 to 1.2), 1.0 (0.8 to 1.3), and 1.3 (1.0 to 1.6) for the 70, 140, and 210-mg groups, respectively.

**Time to Radiographic Evidence of Healing**

The cumulative incidence function estimate of patients who had radiographic evidence of healing at weeks 24 and 52 was similar across treatment groups (range, 66.2% to 78.6% at week 24 and 89.1% to 93.2% at week 52; Table II). There were no apparent dose or treatment-group-related trends in the median time to radiographic evidence of healing (range, 16.4 to 16.9 weeks across groups) and no significant differences between the romosozumab and placebo groups (Table II). Nonunion was reported in 2 patients in the placebo group at week 52.

When evaluated by subgroup (age, sex, fracture type, and fixation type), the results were consistent with the overall study population (data not shown).

**RUSH Scores by Visit**

The RUSH scores improved over time across all treatment groups, plateauing between weeks 36 and 52 (Fig. 4). There were no significant differences in the RUSH scores between the romosozumab and placebo groups at any time. The mean total RUSH scores across treatment groups ranged from 28.2 to 29.1 at week 36 and from 28.5 to 29.6 at week 52.

**HHS**

The HHS improved over time for all of the romosozumab groups and the placebo group. The values were similar between the placebo group and all of the romosozumab groups up to week 24. For weeks 36 and 52, the repeated-measures model

---

**TABLE III Adverse Events**

|                          | Placebo (N = 87) | Subcutaneous Romosozumab |
|--------------------------|------------------|--------------------------|
|                          |                  | 70 mg (N = 60) | 140 mg (N = 89) | 210 mg (N = 89) | Total Romosozumab Group (N = 238) |
| Adverse events during treatment (no. [%]) | 69 (79.3) | 39 (65.0) | 54 (60.7) | 64 (71.9) | 157 (66.0) |
| Serious adverse events† (no. [%]) | 25 (28.7) | 9 (15.0) | 15 (16.9) | 26 (29.2) | 50 (21.0) |
| Acute myocardial infarction | 1 (1.1) | 0 (0.0) | 1 (1.1) | 2 (2.2) | 3 (1.3) |
| Pneumonia | 1 (1.1) | 0 (0.0) | 1 (1.1) | 2 (2.2) | 3 (1.3) |
| Cardiac arrest | 0 (0.0) | 1 (1.7) | 1 (1.1) | 1 (1.1) | 3 (1.3) |
| Hip fracture | 0 (0.0) | 0 (0.0) | 1 (1.1) | 2 (2.2) | 3 (1.3) |
| Postoperative wound infection | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (3.4) | 3 (1.3) |
| Cellulitis | 3 (3.4) | 0 (0.0) | 1 (1.1) | 1 (1.1) | 2 (0.8) |
| Acute pulmonary edema | 1 (1.1) | 0 (0.0) | 0 (0.0) | 2 (2.2) | 2 (0.8) |
| Cardiac failure | 0 (0.0) | 0 (0.0) | 1 (1.1) | 1 (1.1) | 2 (0.8) |
| Cerebrovascular accident | 0 (0.0) | 1 (1.7) | 0 (0.0) | 1 (1.1) | 2 (0.8) |
| Diverticulitis | 0 (0.0) | 0 (0.0) | 1 (1.1) | 1 (1.1) | 2 (0.8) |
| Lower respiratory tract infection | 0 (0.0) | 0 (0.0) | 1 (1.1) | 1 (1.1) | 2 (0.8) |
| Medical device complication | 0 (0.0) | 1 (1.7) | 0 (0.0) | 1 (1.1) | 2 (0.8) |
| Bacterial pneumonia | 0 (0.0) | 1 (1.7) | 0 (0.0) | 1 (1.1) | 2 (0.8) |
| Osteoarthritis | 2 (2.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Fatal adverse events† (no. [%]) | 2 (2.3) | 2 (3.3) | 2 (2.2) | 6 (6.7) | 10 (4.2) |
| Adverse events leading to discontinuation of investigational product (no. [%]) | 4 (4.6) | 2 (3.3) | 5 (5.6) | 3 (3.4) | 10 (4.2) |
| Adverse events leading to study discontinuation (no. [%]) | 2 (2.3) | 1 (1.7) | 2 (2.2) | 2 (2.2) | 5 (2.1) |
| Adverse events of interest§ (no. [%]) | 2 (2.3) | 1 (1.7) | 0 (0.0) | 2 (2.2) | 3 (1.3) |
| Hypersensitivity | 0 (0.0) | 0 (0.0) | 1 (1.1) | 0 (0.0) | 1 (0.4) |
| Hypocalcemia | 1 (1.1) | 1 (1.7) | 0 (0.0) | 1 (1.1) | 2 (0.8) |
| Injection-site reactions | 1 (1.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Hyperostosis# | 1 (1.1) | 0 (0.0) | 1 (1.1) | 2 (2.2) | 3 (1.3) |
| Malignancy | 2 (2.3) | 4 (6.7) | 5 (5.6) | 2 (2.2) | 11 (4.6) |

* N = number of patients randomized who received ≥1 dose of investigational product. † Includes those that occurred in at least 2 patients in the total romosozumab or placebo group. ‡ Fatal events were reported as death (day 273) and coronary artery hemorrhage (day 3) in the placebo group; respiratory failure (day 3) and cardiac arrest (day 72) in the 70-mg romosozumab group; cardiac arrest (day 14) and cardiac failure (day 187) in the 140-mg romosozumab group; and cardiac arrest (day 2), cardiopulmonary arrest (day 75), cerebrovascular accident (day 258), bacterial pneumonia (day 3), cardiac disorder (day 119), and acute respiratory failure (day 12) in the 210-mg romosozumab group. § Adverse events of interest at the time of this study were prospectively defined. # Reported as extraskeletal ossification.
indicated a significant difference for the 140-mg romosozumab group, favoring romosozumab compared with placebo. At week 36, the LSM (and 95% CI) was 86.8 (83.5 to 90.2) in the 140-mg romosozumab group and 80.3 (77.0 to 83.6) in the placebo group (p = 0.0062). At week 52, the LSM (and 95% CI) was 89.0 (85.9 to 92.1) in the 140-mg romosozumab group and 84.3 (81.3 to 87.4) in the placebo group (p = 0.0365). However, this was likely a chance finding, as the p values were not corrected for multiplicity and the 210-mg group did not show a significant difference.

**VAS Hip Pain**
The difference in the LSM VAS hip pain between the placebo group and individual romosozumab groups was not significant at any time point.

**Safety**
A total of 325 patients (87 in the placebo group and 238 in the total romosozumab group) received ≥1 dose of the investigational product over the 12-week dosing period and were included in the 52-week safety analysis. Sixty-nine patients (79.3%) in the placebo group and 157 (66.0%) in the total romosozumab group reported ≥1 adverse event that emerged during treatment (Table III). No trends were apparent in the pattern or types of adverse events across treatment groups; however, a higher percentage of patients in the romosozumab group than in the placebo group reported back pain (6.7% versus 0%), arthralgia (5.9% versus 2.3%), and a lower percentage reported constipation (8.8% versus 12.6%), diarrhea (3.8% versus 9.2%), and pain in an extremity (0.8% versus 5.7%).

Serious adverse events were reported for 25 (28.7%) of the patients in the placebo group and 50 (21.0%) in the total romosozumab group; no serious adverse event was reported for >3 patients in any group. Serious adverse events in the system order class of cardiac, vascular, and nervous system disorders were generally comparable between groups, except for cardiac disorders (placebo, 3.4%; total romosozumab group, 5%), most of which occurred during the follow-up period. Adverse events leading to discontinuation of use of the investigational product or participation in the study were comparable between treatment groups (Table III).

Adverse events of interest included hypersensitivity, hypocalcemia, injection-site reactions, hyperostosis, malignancy, and osteoarthritis; all were comparable among treatment groups (Table III). Of note, 1 patient (in the 210-mg romosozumab group) had a serious hypersensitivity adverse event of acute generalized exanthematous pustulosis on study day 2 that resolved with topical steroid treatment; 1 (140-mg group) had a non-serious adverse event of hypocalcemia (day 10) in the setting of congestive heart failure; 1 (210-mg group) had a serious adverse event of acute myeloid leukemia after the last injection; and 2 (placebo group) had serious adverse events of radiographically evident worsening of preexisting osteoarthritis, with 1 of them also having worsening of symptoms of preexisting osteoarthritis.

None of the patients who received romosozumab stopped using it because of injection-site reactions, and none of the adverse events were suggestive of osteonecrosis of the jaw or atypical femoral fracture. Ten (4.2%) of the patients in the total romosozumab group and 2 (2.3%) in the placebo group had fatal adverse events; none were considered related to the investigational product (Table III).

Anti-romosozumab binding antibodies were detected in 20 (9.4%) of 213 patients treated with romosozumab and were transient in 8 of them. The transient neutralizing antibodies to romosozumab were detected in 5 patients (2.3%) and did not appear to affect the safety profile of romosozumab.

**Discussion**
Although romosozumab was shown to increase bone formation, reduce bone resorption, improve BMD, and decrease fracture rates in postmenopausal women11,13, stimulation of bone formation associated with short-term romosozumab treatment did not significantly accelerate fracture-healing following hip fracture fixation in our study population. The TUG scores and median time to radiographic healing were similar across treatment groups and were within the range observed in other hip-fracture-fixation studies of patients with comparable demographics11-15. The RUSH scores at the end of the study period indicated that almost all fractures were sufficiently healed.

The prevalence of adverse events was comparable among the treatment groups and consistent with the type of events that would be expected in this population of mostly elderly patients. A slightly higher prevalence of cardiac serious adverse events was reported in the romosozumab groups, and while some were recorded during the active treatment phase, most occurred during the follow-up period. The heterogeneous nature of the reported events, their low number, and a 3:1 randomization may limit definitive interpretation. Two much larger pivotal fracture trials of women with postmenopausal osteoporosis showed discordant results with regard to the number of positively adjudicated cardiovascular serious adverse events12,13. While a higher number was observed in the romosozumab group in the trial comparing romosozumab with alendronate14, no difference was observed in the larger, 7,000-patient placebo-controlled trial15.

Similar to the current study, a pair of trials comparing teriparatide with a placebo showed no acceleration of hip fracture-healing in the teriparatide group16. In a study comparing the effects of teriparatide and risedronate on recovery after hip fractures7, patients in the teriparatide group completed the TUG test in a shorter time, but there was no significant difference in the time to radiographic evidence of healing; the authors noted that the TUG test was a secondary end point, and the results should be interpreted with caution7. The time to radiographic evidence of healing in the teriparatide versus risedronate study was approximately 12 weeks in both arms compared with 16 weeks in our study; probably because of differences in the study populations—the teriparatide study enrolled patients with low-trauma pertrochanteric hip fractures. The reason for the absence of accelerated healing, despite stimulation of bone formation, is unclear. In our study, patients were treated at sites carefully selected for high surgical standards of care, and they had an overall rapid improvement in their functional scores and radiographic signs of healing regardless of treatment group. The
near-perfect RUSH scores at week 36 suggest that complete fracture-healing had occurred in most patients by that time. Our study had several methodological strengths, including stratified randomization to reduce possible bias as well as the use of outcome measures proven to be valid and achievable in elderly populations and patients with hip fracture.20,23,26. The study population, however, may not have been at sufficient risk for delayed healing to demonstrate benefit from an intervention for acceleration of fracture-healing.

Our study has some limitations. The TUG tests were performed locally and not recorded with videography; therefore, no central adjudication of the results was possible. Intertrochanteric fractures, the most common type of fracture in our study, are usually not complicated by issues with fracture union, and it is plausible that the lack of treatment effect in our study was due to the inclusion of these fracture types. In addition, we were unable to fully assess prefracture morbidity, but since this was a randomized study, outcomes were unlikely to have been confounded by presurgery imbalances. Finally, differences among the sites regarding patient instruction and encouragement for the TUG test, which is considered challenging in this patient population, are possible and may have skewed some of the results; a patient-reported outcome measure reflecting improvement in quality of life might have been a more appropriate end point.

This phase-2 dose-finding study did not identify a difference with respect to its primary end point and adds to published evidence21,23 failing to show acceleration of fracture-healing with the use of bone-forming agents at the doses and schedules tested in the respective study populations. The quality of the surgical devices and methods used at the academic centers in our study likely outweighed any effect of romosozumab on fracture-healing. Future studies should focus on augmentation of fracture repair when fracture-healing is at risk or potentially delayed or compromised.

**Appendix**

Supporting material provided by the authors is posted with the online version of this article as a data supplement at jbjs.org (http://links.lww.com/JBJS/F703).

Emil H. Schemitsch, MD, FRCS(C)1
Theodore Miclau, MD2,3

**References**

1. Odén A, McCloskey EV, Johansson H, Kanis JA. Assessing the impact of osteoporosis on the burden of hip fractures. Calcif Tissue Int. 2013 Jan;92(1):42-9. Epub 2012 Nov 8.
2. Johneil O, Kanis JA. An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int. 2004 Nov;15(11):897-902. Epub 2004 May 4.
3. Bentler SE, Liu L, Obrizan M, Cook EA, Wright KB, Geweke JF, Chrischilles EA, Pavlik CE, Wallace RB, Ohsfeldt RL, Jones MP, Rosenthal GE, Wolinsky FD. The aftermath of hip fracture: discharge placement, functional status, change, and mortality. Am J Epidemiol. 2009 Nov 15;170(10):1290-9. Epub 2009 Oct 4.
4. International Osteoporosis Foundation. Facts and statistics. Accessed 2019 Sep 13. https://www.iofbonehealth.org/facts-statistics#category-16
5. Kanakaris NK, West RM, Giannoudis PV. Enhancement of hip fracture healing in the elderly: evidence deriving from a pilot randomized trial. Injury. 2015 Aug;46(8):1425-8.
6. Huang TW, Chuang PY, Lin SJ, Lee CY, Huang KC, Shih NN, Lee MS, Hsu RW, Shen WJ. Teriparatide improves fracture healing and early functional recovery in treatment of osteoporotic intertrochanteric fractures. Medicine (Baltimore). 2016 May;95(19):e3626.
7. Aspenberg P, Malouf J, Tarantino U, García-Hernández PA, Corradini C, Overgaard S, Stepans J, Borris L, Lespessailles E, Frijhagen F, Papavassiliou K, Petto H, Caeiro

Theofilos Karachalios, MD4
Lauren L. Nowak, MSc1
Parag Sancheti, FRCS(Ed), MS(Orth), DNB(Orth), MCh(UK), PhD5
Rudolf W. Poolman, MD, PhD6
John Caminis, MD7
Nadia Daizadeh, PhD8
Ricardo E. Dent-Acosta, MD8
Ogo Egbuna, MD, MSc8
Arkadi Chines, MD8
Judy Maddox, DO8
Andreas Grauer, MD8
Mohit Bhandari, MD, PhD9

1Department of Surgery, University of Western Ontario, London, Ontario, Canada
2Department of Orthopaedic Surgery, University of California, San Francisco, San Francisco, California
3Orthopaedic Trauma Institute, Zuckerberg San Francisco General Hospital, San Francisco, California
4Orthopaedic Department UGHL, School of Health Sciences, University of Thessalia, Larissa, Greece
5Sancheti Institute of Orthopaedics and Rehabilitation, Pune, India
6Joint Research, OLVG, Amsterdam, the Netherlands
7Sanofi Genzyme, Bridgewater, New Jersey
8Amgen, Inc., Thousand Oaks, California
9McMaster University, Hamilton, Ontario, Canada

Email address for E.H. Schemitsch: emil.schemitsch@lhsc.on.ca

ORCID iD for E.H. Schemitsch: 0000-0002-6435-9069
ORCID iD for T. Miclau: 0000-0003-1975-2061
ORCID iD for T. Karachalios: 0000-0002-9043-0535
ORCID iD for L.L. Nowak: 0000-0002-4388-3128
ORCID iD for P. Sancheti: 0000-0002-8903-1430
ORCID iD for R.W. Poolman: 0000-0003-3178-2247
ORCID iD for J. Caminis: 0000-0002-8734-7327
ORCID iD for N. Daizadeh: 0000-0002-4136-4068
ORCID iD for R.E. Dent-Acosta: 0000-0003-3436-0031
ORCID iD for O. Egbuna: 0000-0003-0548-3809
ORCID iD for A. Chines: 0000-0003-3682-6798
ORCID iD for J. Maddox: 0000-0001-7214-0545
ORCID iD for A. Grauer: 0000-0001-3988-8262
ORCID iD for M. Bhandari: 0000-0003-3556-9179

Emil H. Schemitsch, MD, FRCS(C)
evenity pi hcp english.aashx

1. Podsiadlo D, Richardson S. The Timed Up & Go Test, a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991 Feb;39(2):142-8.

2. Bhandari M, Chiavaras MM, Bassi R, Choudhur H, Ayeni O, Chakravertty R, Bains S, Sprague S, Petrisor B; Assessment Group for Radiographic Evaluation and Evidence (AGREE) Study Group (AGREE Investigators Writing Committee). Assessment of radiographic fracture healing in patients with operatively treated femoral neck fractures. J Orthop Trauma. 2013 Sep;27(8):e219-9.

3. Malouf-Sierra J, Tarantino U, García-Hernández PA, Corradini C, Øvergaard S, Stepán JJ, Borris L, Lespesiailles E, Frihagen F, Papavasiliou K, Petto H, Aspengren P, Caeiro JR, Marin F. Effect of teriparatide or risedronate in elderly patients with a recent percutaneous hip fracture: final results of a 78-week randomized clinical trial. J Bone Miner Res. 2017 May;32(5):1040-51. Epub 2017 Jan 26.

4. Angen Inc. EVENTY™ (romosozumab-aqqg) injection, for subcutaneous use. 2019 Apr. Accessed 2019 Sep 4. https://www.pl.angen.com/~/media/angen/repositories/pi-angencom/eventy/eventy_pihcpenglish.aspx

5. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014 Jan 30;370(5):412-20. Epub 2014 Jan 1.

6. Cosman F, Cittadini DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyachi A, Zerin CM, Millmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016 Oct 20;375(16):1532-43. Epub 2016 Sep 18.

7. Saag KG, Peterson J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017 Oct 12;377(15):1417-27. Epub 2017 Sep 11.

8. Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F, Samadfam R, Jolette J, Smith SY, Stolina M, Lacey DL, Simonet WS, Paszty C, Li G, Ke HZ. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res. 2011 May;26(5):1012-21.

9. Cui L, Cheng H, Song C, Li C, Simonet WS, Ke HZ, Li G. Time-dependent effects of sclerostin antibody on a mouse fracture healing model. J Musculoskelet Neuronal Interact. 2013 Jun;13(2):178-84.

10. Suen PK, He YX, Chow DH, Huang L, Li C, Ke HZ, Ominsky MS, Qin L. Sclerostin monoclonal antibody enhanced bone fracture healing in an open ostectomy model in rats. J Orthop Res. 2014 Aug;32(8):997-1005. Epub 2014 Apr 30.

11. Padhi D, Allison M, Kivitz AJ, Gutiérrez MJ, Stouch B, Wang C, Jang G. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blinded, placebo-controlled study. J Clin Pharmacol. 2014 Feb;54(2):168-78. Epub 2013 Dec 11.

12. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, intravenous injection of sclerostin antibody enhanced bone fracture healing in an open ostectomy model in rats. J Orthop Res. 2014 Aug;32(8):997-1005. Epub 2014 Apr 30.

13. Reindl R, Harvey EJ, Berry GK, Rahme E; Canadian Orthopaedic Trauma Society (COTS). Intramedullary versus extramedullary fixation for unstable intertrochanteric fractures: a prospective randomized controlled trial. J Bone Joint Surg Am. 2015 Dec 2;97(12):1905-12.

14. Matre K, Virje T, Havelin Li, Gjertsen JE, Funes O, Espehauge B, Kjellevold SH, Fevang JM. TRIGEN INTERTAN intramedullary nail versus sliding hip screw: a prospective, randomized multicenter study on pain, function, and complications in 684 patients with an intertrochanteric or subtrochanteric fracture and one year of follow-up. J Bone Joint Surg Am. 2013 Feb 6;95(3):200-8.

15. Boese CK, Buecking B, Schwarting T, Debus F, Ruchholtz S, Blienem C, Frink M, Lechner P. The influence of pre-existing radiographic osteoarthritis on functional outcome after trochanteric fracture. Int Orthop. 2015 Jul;39(7):1405-10. Epub 2015 Jan 21.

16. Herrera A, Domingo LJ, Calvo A, Martínez A, Cuencova J. A comparative study of trochanteric fractures treated with the Gamma nail or the proximal femoral nail. Int Orthop. 2002;26(6):365-9. Epub 2002 Jul 31.

17. Zhu F, Liu G, Shao HG, Wang YJ, Li RQ, Yang HL, Geng DC, Xu YZ. Treatment of femoral neck fracture with percutaneous compression plate: preliminary results in 74 patients. Orthop Surg. 2015 May;7(2):132-7.